Update in Bladder Cancer - SPOC

Webinar Information

Webinar Description

Matthew I. Milowsky, MD, FASCO, will discuss aspects of bladder cancer including the role of biomarkers in the management of bladder cancer, the role of perioperative therapy for muscle-invasive bladder cancer, and treatment strategies for advanced/metastatic bladder cancer.

Learning Objectives

  • Discuss the role of biomarkers in the management of bladder cancer
  • Describe the role of perioperative therapy for muscle-invasive bladder cancer
  • Identify treatment strategies for advanced/metastatic bladder cancer

 

Webinar Documents

Handouts

 

Webinar Registration


Take Course

You must have an account and be logged in to register. Please contact us with any questions at [email protected] or (919) 445–1000.

 

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 ODS
  • 1.25 NCPD/CNE
  • 1.00 Participation
Course opens: 
03/19/2025
Course expires: 
03/18/2027
Research to Practice Logo 

Cancer Treatment in North Carolina: Research to Practice (formerly Medical and Surgical Oncology) webinars cover the spectrum of anti-cancer therapy, with a focus on recent research developments, both locally and at large, and what’s ready for regular practice. Perspectives from medical oncology, radiation oncology, and surgery will be included.

This series incorporates an understanding of practice dynamics and concerns throughout the state of North Carolina, and the availability of clinical trials and subspecialty expertise to inform care.

These webinars provide FREE continuing education credit.

Photo of Matthew I. Milowsky, MD, FASCO 

Matthew I. Milowsky, MD, FASCO

Distinguished Professor of Medicine
Division of Oncology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Disclosures

Activity Directors
This activity has been planned and implemented under the sole supervision of the Course Director, Stephanie Wheeler, PhD, MPH, and Emily Ray, MD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Wheeler received research support from AstraZeneca (ended June 2023) and Pfizer Medical Foundation (ended December 2023). These financial relationships have been mitigated. Dr. Emily Ray has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/unclcn-webinar-planning-committee.

ANCC
The presenter receives consulting fees from G1 Therapeutics and research support from ALX Oncology, Arvinas, AstraZeneca/MedImmune, Bristol Myers Squibb, Clovis Oncology, G1 Therapeutics, Incyte, Loxo, Merck, Mirati Therapeutics, Novartis, and Roche/Genentech. These financial relationships have been mitigated through slide review by UNC CPD.

 

Accreditation Statements

The following accrediting agencies have approved this course for continuing education credits. Participants should understand that their individual participation and claiming credit must abide by the regulations set forth by their respective accrediting agency. No partial credit will be provided.

1.25 NCPD/CNE
UNC Health is approved as a provider of nursing continuing professional development by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Criteria for successful completion to claim CE Certificate requires attendance at the NCPD activity, and submission of an evaluation within 7 days.

1.00 ACPE Pharmacist
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit can be viewed and printed in CPE Monitor in approximately 2 to 3 weeks.

The Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 1.0 ACPE Credit(s).

1.00 ACPE Pharmacy Tech
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit can be viewed and printed in CPE Monitor in approximately 2 to 3 weeks.

The Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 1.0 ACPE Credit(s).

1.00 ODS/CTR
Approved by the National Cancer Registrars Association (NCRA).

This activity is worth 1 credit hour and is approved by the NCRA.

1.50 ASRT
Approved by the American Society of Radiologic Technologists (ASRT).

This activity is worth 1 credit hour and is approved by the ASRT.

 

Notice

In most cases, regulations prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to view a minimum of 53 minutes of the live webinar video to receive CE credit. Please contact your individual accreditation agencies for more details.

Altering or submitting modified certificates constitutes fraud that can result in punitive action by the accrediting agency.

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 ODS
  • 1.25 NCPD/CNE
  • 1.00 Participation
Please login or register to take this course.

You must have an account and be logged in to register for and to access the course.

Requirements for Receiving Free Continuing Education Credits

  • Watch the video
  • Complete the assessment with a score of 80% or better
  • Complete the evaluation
  • Download the appropriate certificate

Please see our detailed instructions for more information on completing the Self-Paced, Online Courses and receiving credit.